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Abstract
Poly-ADP-ribose-polymerase inhibitor (PARPi) treatment is indicated for advanced-stage ovarian tumors with BRCA1/2
deﬁciency. The “BRCAness” status is thought to be attributed to a tumor phenotype associated with a speciﬁc epigenomic
DNA methylation proﬁle. Here, we examined the diagnostic impact of combined BRCA1/2 sequence, copy number, and
promoter DNA methylation analysis, and evaluated whether genomic DNA methylation patterns can predict the BRCAness
in ovarian tumors. DNA sequencing of 172 human tissue samples of advanced-stage ovarian adenocarcinoma identiﬁed
36 samples with a clinically signiﬁcant tier 1/2 sequence variants (point mutations and in/dels) and 9 samples with a CNV
causing a loss of function in BRCA1/2. DNA methylation analysis of the promoter of BRCA1/2 identiﬁed promoter
hypermethylation of BRCA1 in two mutation-negative samples. Computational modeling of genome-wide methylation
markers, measured using Inﬁnium EPIC arrays, resulted in a total accuracy of 0.75, sensitivity: 0.83, speciﬁcity: 0.64,
positive predictive value: 0.76, negative predictive value: 0.74, and area under the receiver’s operating curve (AUC): 0.77, in
classifying tumors harboring a BRCA1/2 defect from the rest. These ﬁndings indicate that the assessment of CNV and
promoter DNA methylation in BRCA1/2 increases the cumulative diagnostic yield by 10%, compared with the 20% yield
achieved by sequence variant analysis alone. Genomic DNA methylation data can partially predict BRCAness in ovarian
tumors; however, further investigation in expanded BRCA1/2 cohorts is needed, and the effect of other double strand DNA
repair gene defects in these tumors warrants further investigations.
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The application of chemotherapy as the standard treatment
for advanced-stage ovarian cancer has been associated with
little progress in improving the long-term clinical outcomes
[1]. This has led to more targeted therapeutic approaches
in the management of ovarian cancer including the use of
poly-ADP-ribose-polymerase inhibitors (PARPis). PARP
inhibitors induce targeted tumor cell death in homologous
recombination repair-deﬁcient cells (e.g., those with
BRCA1/2 deﬁciency) through the exploitation of synthetic
lethality [2]. Initial Phase-II clinical trials have shown a
signiﬁcantly longer progression-free survival in the PARPitreated patients as compared with those receiving placebo
(8.4 vs. 4.8 months), with a more pronounced effect in
subjects that had germline or somatic BRCA1/2 mutations
(11.2 vs. 4.3 months) [3]. Subsequently, randomized controlled trials (RCTs) have shown improved progression-free
survival in BRCA1/2 mutation carriers when PARPis are
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used in the upfront maintenance setting (HR 0.3, 95% CI
0.23–0.41, P < 0.0001) and when used as maintenance in
the recurrent setting (19.1 vs. 5.5 months, HR 0.30, 95% CI
0.22–0.41, p < 0.0001) [4, 5]. PARPis have thus been
clinically approved for use in ovarian cancer patients with
either germline or somatic BRCA1/2 mutations [2, 4, 6].
Genetic testing is now being performed to detect somatic
or germline mutations in BRCA1/2 to determine the eligibility for PARP inhibitors [6]. The detected variants are
assessed according to the CAP/AMP classiﬁcation guidelines [7], with tier 1 and tier 2 being eligible for PARPi
therapy. For some patients, however, variants of uncertain
clinical signiﬁcance (VUS or Tier 3) are identiﬁed, which
results in challenges in deciding on the appropriate therapeutic approach. In addition, some laboratories do not
systematically evaluate other causes of BRCA deﬁciency
such as copy-number variation (CNV) or aberrant promoter
methylation of the BRCA1/2 genes. These events can induce
an abnormal protein dosage comparable to the effect by
sequence variants [8]. Therefore, a portion of the patients
that beneﬁt from PARPi therapy is not identiﬁed.
We have previously demonstrated that the implementation of copy-number variant assessment in clinical testing
can signiﬁcantly increase the detection yield in genetic
testing [9]. We have also shown that haploinsufﬁciency of
numerous genes in congenital disorders results in speciﬁc
DNA methylation patterns across the genome, which can
assist the diagnosis of the patients with an uncertain clinical
diagnosis or those carrying VUSs [10–16]. DNA methylation proﬁling has frequently been used to classify tumor
subtypes [17, 18] and prediction of treatment outcomes [19]
in various cancers. In particular, a BRCA1-associated DNA
methylation signature has been identiﬁed in the peripheral
blood [20] and an attempt has been made to assess the
pathogenicity of BRCA1 unclassiﬁed genetic variants in
breast cancer using DNA methylation proﬁling [21]. In
ovarian cancer, it is established that tumors in which
homologous recombination DNA repair defect is present,
including those with BRCA’s deﬁciency, have a relatively
distinct clinical and molecular phenotype, a concept referred
to as BRCAness [22]. We hypothesize that such ovarian
tumors have a distinct genomic DNA methylation pattern
utilizing which, in conjunction with CNV and sequence
variant assessment, can assist the identiﬁcation of the
patients who may beneﬁt from PARP inhibitor therapy.
Here, we describe a comprehensive clinical testing
approach for the assessment of the BRCA1/2 genes in ovarian
cancer specimens, which can be used to determine patients’
eligibility for PARP inhibitor therapy. We describe the overall
clinical diagnostic yield as determined by sequence variant
analysis and evaluate the improvements achieved by the
incorporation of CNV and promoter DNA methylation evaluation of BRCA1/2. In addition, we describe a computational
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model for the assessment of BRCA1/2-associated genomic
DNA methylation patterns in tumor tissues and examine the
ability of this classiﬁer to distinguish the patients that may
beneﬁt form PARP inhibitor therapy.

Methods
Patients and samples
Patient tissue specimens were obtained from tissue archive
of deceased patients treated at the London Regional Cancer
Program (LRCP, London, ON, Canada) between 2007 and
2012. All were under the age of 80 years, and treated for
invasive high-grade serous, stage 3c or 4, epithelial ovarian
carcinoma. Archival formalin-ﬁxed parafﬁn-embedded
(FFPE) slides of ovarian tissues from surgical resections
were reviewed to conﬁrm the diagnosis of high-grade serous carcinoma. Appropriate blocks with optimal tumor
content were selected for analysis. This means that the
cumulative tumor percentage of different blocks of each
individual should be above 50%. Using a clean protocol
(100% alcohol followed by DNAaway and then again with
100% alcohol), tissue blocks were cut at 20 μm sections
with three sections, each placed in two tubes. Genomic
DNA was then isolated using the Invitrogen RecoverAll
total nucleic acid isolation kit (Thermo Fisher Scientiﬁc,
Waltham, MA, USA) according to the manufacturer’s
protocol. DNA quantiﬁcation and genomic proﬁle were then
assessed with the 2200 TapeStation (Agilent Technologies,
Santa Clara, CA, USA).

High-throughput DNA sequencing
Extracted genomic DNA samples were placed into three
groups based on genomic proﬁle size ranges of <700 bp,
700–1100 bp, and 1100–2500 bp, and were subject to
fragmentation to 180–220 bp using a Covaris E220 Series
Focused-ultrasonicator (Covaris, Inc., Woburn, MA) with
recommended settings and treatment times of 20, 50, and
60 s, respectively. Libraries were then prepared with the
SeqCap EZ HyperCap workﬂow according to manufacturer’s protocol (Roche NimbleGen, Inc., Madison, WI,
USA) and captured as a 24-plex pool with a custom target
design that enriched for all coding exons, as well as 20 bp of
the 5′ and 3′ ﬂanking intronic regions for 37 hereditary
cancer genes. Four captured libraries (96 samples) were
diluted to 4 nM each and pooled for sequencing on the
NextSeq according to the manufacturer’s protocol (Illumina, San Diego, CA, USA). The libraries were sequenced
using the NextSeq version 2 mid output reagent kit to
generate 2 × 150 bp paired-end reads. Post-sequencing ﬁle
conversion generated FASTQ ﬁles for sequence alignment
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with the NextGene software version 2.4.1 (SoftGenetics,
LLC, State College, PA, USA) using the recommended
settings. The identiﬁed variants were ﬁltered by an allelic
fraction >10% and were assessed based on CAP guidelines
for pathogenicity.

Detection of copy-number variants
Base coverage distribution reports were created using
NextGene software (SoftGenetics, LLC, USA) and processed through a normalization algorithm described previously [9] using a reference population of whole blood
controls. Whole gene deletions and duplications for BRCA1
or BRCA2 that had at least a 30% allelic fraction were
identiﬁed by concordance across four parameters: raw
values (average normalized value per sample per gene),
intra-sample ratio (ratio of average normalized value per
gene of interest to average normalized value of the
remaining genes on the panel (n = 36)), FFPE inter-sample
ratio (ratio of average normalized value per gene to average
normalized values of the same gene from other FFPE
samples—Table S1), and whole blood inter-sample ratio
(ratio of average normalized value per gene to average
normalized values of the same gene from whole blood
control samples). Sub-gene level events were identiﬁed by a
minimum of 50% deviation from the normalized values of
the remainder of the gene.

Conﬁrmation testing for sequence variants and
CNVs
Sanger sequencing was performed on selected sequence variants (minimum 20% allelic fraction, PCR fragment size
<300 bp based on current in-house primer stock) with the
BigDye Terminator version 1.1 cycle sequencing kit (Life
Technologies, USA). Sequencing products were separated by
capillary electrophoresis on ABI 3730 (Life Technologies,
USA) and were analyzed with Mutation Surveyor version
4.0.7 software (SoftGenetics, LLC, USA). Multiplex ligationdependent probe ampliﬁcation (MLPA) analysis was carried
out for all copy-number variants >30% according to the
manufacturer’s recommendations using SALSA MLPA kits
P0002-BRCA1-D1 and P090-BRCA2-A4 (MRC Holland,
Amsterdam, Netherlands). PCR products were separated by
capillary electrophoresis on an ABI 3730 (Life Technologies)
and analyzed with WB and FFPE references with Coffalyzer.
Net software version 131211.1524 (MRC Holland).

DNA methylation analysis
Of the samples processed in this study, 80 were selected for
DNA methylation analysis. This included all of the samples
with a clinically signiﬁcant (Tier I/II) BRCA1 or BRCA2
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variants together with a matching number of samples
without any mutation in BRCA1 or BRCA2. Following
bisulﬁte conversion, DNA methylation analysis of the
samples was performed using the Illumina Inﬁnium
methylation EPIC bead chip arrays, according to the manufacturer’s protocol. This array includes >860,000 human
genomic methylation CpG sites, including 99% of RefSeq
genes, all of the known disease-associated imprinted loci in
humans, and 96% of CpG islands. The resulting methylated
and unmethylated signal intensity data were imported into R
3.5.2 for analysis. Normalization was performed according
to the Illumina normalization method with background
correction using the minﬁ package. The methylation level
for each probe was measured as a beta value, calculated
from the ratio of the methylated signal intensity versus the
total sum of unmethylated and methylated signal intensities
for that probe, ranging between 0 (no methylation) and 1
(complete methylation). Probes with detection p values >
0.1, those located on chromosomes X and Y, those known
to contain a SNP at the CpG interrogation or single
nucleotide extension, and probes known to cross-react with
chromosomal locations other than their target regions were
excluded from analysis. All of the samples were examined
for genome-wide methylation density to ensure evidence of
bimodal distribution of the genomic DNA methylation
levels. The majority of the samples were analyzed in one
batch and only a few of them were processed in a different
batch. Factor analysis using a principal component analysis
was performed to examine the batch effect and identify
potential outliers. No batch effect was observed between the
samples processed among the two batches. Following
quality controls, the methylation levels at the promoters of
BRCA1 and BRCA2 were examined for an evidence of gain
of methylation in the immediate 5′ promoter region in
BRCA1/2 mutation-negative specimens.

Computational modeling of BRCA1/2 positive
samples
A ﬁvefold cross validation using six different models and
their ensembles was performed to examine whether the
status of BRCA1/2 loss of function can be modeled using
the DNA methylation data. The data were randomly divided
into ﬁvefolds. Fourfold was used for feature selection and
model training while the remaining fold was used for testing
the trained model. The process was repeated ﬁve times so
that all of the folds were used for at least once during both
testing and training. Feature selection was performed following three steps: (1) probes with a mean methylation
difference of >0.05 between BRCA1/2 positive and negative
samples were retained; (2) probes were sorted based on the
area under the receiver’s operating characteristic’s curve
(AUC) and the top 1000 with the greatest AUC were
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retained; (3) a pair-wise correlation coefﬁcient was measured for every probe, separately among the cases and
controls, and highly correlated features (R-squared > 0.8)
were excluded. Six different models were used for training
including elastic net regression, support vector machine
(SVM) with linear kernel, SVM with radial basis function
kernel, linear discriminant analysis, random forest, and
Bayesian generalized linear model. The ensemble of these
models was conducted according to the pipeline implemented in the SuperLearner R package. Using a least
absolute shrinkage and selection operator, each model was
assigned a coefﬁcient to be used for combining the predictions by multiple classiﬁers into the ﬁnal classiﬁcation.
After repeating this procedure for all of the ﬁvefolds, the
average prediction accuracy measures on the testing set,
including the total accuracy, sensitivity, speciﬁcity, positive
predictive value (PPV), negative predictive value (NPV),
and AUC were reported.

Results
Reportable sequence variants in BRCA1 and BRCA2
DNA sequence analysis for BRCA1 and BRCA2 was conducted in a cohort containing 172 samples from patients
with advanced-stage high-grade serous epithelial ovarian
adenocarcinoma. The samples were analyzed using a
custom-designed multi-gene NGS panel for BRCA1 and
BRCA2. The NGS analysis identiﬁed 36 samples with at
least one clinically signiﬁcant (Tier I/II) variant. Of these,
27 patients had a variant classiﬁed as Tier I (15 BRCA1
mutations and 12 BRCA2 mutations), with 1/27 having both
a Tier I and a Tier II variant and 5/27 having both a Tier 1
and Tier III variant. There were also six samples with only
VUS (Tier III) in BRCA1 or BRCA2 (Table 1).

BRCA1 and BRCA2 copy-number variants
The CNV analysis identiﬁed a total of ten subjects with a
CNV involving BRCA1 (four full gene duplications, four
full gene deletions, and two BRCA1 exon 13 duplications—
Table 1). In addition, there were 11 cases with a CNV
overlapping BRCA2, including 8 samples with duplications
and 3 with deletions of the entire gene. Among none of the
samples with deletions (duplications are not eligible for
PARPi therapy), the primary sequence variant assessment
had not identiﬁed a reportable sequence variant (Table 1).

DNA methylation analysis of the BRCA1/2 promoters
A total of 130 samples were deemed negative for any
BRCA1 and BRCA2 reportable sequence variants or CNVs,
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among which 38 were subject to DNA methylation testing.
The methylation analysis of the promoters of BRCA1 and
BRCA2 identiﬁed two additional patients with increased
methylation levels of up to 60% (consistent with hypermethylation of one of the two alleles) as compared with the
rest of the samples, all of which were fully hypomethylated
(median cross-region methylation level <15%, Fig. 1). This
indicated a 5% increase in the diagnostic yield of samples
negative in BRCA sequence variant testing. In addition,
none of the patients with a reportable sequence variant in
BRCA’s showed hypermethylation in the promoter of
BRCA1 or BRCA2, indicating that the patients with BRCA’s
loss of function due to pathogenic variants, do not have
additional promoter hypermethylation.

Classiﬁcation of ovarian tumors by BRCA status
using DNA methylation data
We attempted, using an ensemble learning approach, to
determine whether samples with and without BRCA1/2
mutations can be classiﬁed using the genome-wide DNA
methylation data. DNA methylation proﬁling was performed on a total of 44 samples with BRCA1/2 loss of
function variants and 36 samples without a reportable variant or a promoter DNA methylation aberration in BRCA1/
2. Following feature selection, six different classiﬁcation
models were developed among which SVM with linear
kernel reached the highest accuracy and was most consistently selected to be included in the ﬁnal ensemble.
Therefore, at the ensemble, the predictions of most models
other than SVM were down-weighted. The average classiﬁcation accuracies of the ﬁnal model as determined during
the ﬁvefold cross-validation on the testing set—not used for
feature selection or model training—were as follows: total
accuracy: 0.75, sensitivity: 0.83, speciﬁcity: 0.64, PPV:
0.76, NPV: 0.74, and AUC: 0.77 (Tables 2, S2, and S3).
These results indicated that DNA methylation data can
partially predict the status of BRCA deﬁciency in ovarian
cancer tumors.

Discussion
Utilization of high-throughput sequencing has become a
common practice in the clinical testing of constitutional and
somatic disorders. These assays enable for thorough
screening of single nucleotide variants and short indels,
while larger indels, extensive copy-number changes, and
other causes of gene function aberrations, such as defects in
DNA methylation, remain unexplored in most clinical
assessments. An example of this applies to the genetic
testing of BRCA1/2 in ovarian cancer. In this study, we have
demonstrated that ~20% of the ovarian tumors can be
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Table 1 Reportable sequence variants and CNVs in BRCA1 and BRCA2
Sample ID Tier 1

Tier 2

Tier 3 (VUS)

CNVs

1105-001* BRCA1:c.3254_3255dupGA,
p.(Leu1086Aspfs*2) (57.6%)
1105-009* BRCA1:c.1961dupA,
p.(Tyr655Valfs*18) (33.9%)
1105-039*

BRCA1
exon13dup

1105-054* BRCA1:c.5266dupC,
p.(Gln1756Profs*74) (58.4%)
1105-057* BRCA1:c.5095C>T,
p.(Arg1699Trp) (44.2%)
1105-112* BRCA1:c.5207T>C,
p.(Val1736Ala) (84.7%)
1105-155* BRCA1:c.4327C>T, p.(Arg1443*)
(46.1%)
1105-162* BRCA1:c.212+3A>G (96.7%)
1105-195* BRCA1:c.5059delG,
p.(Val1687Leufs*3) (51.3%)
1105-207*
1105-227* BRCA1:c.5266dupC,
p.(Gln1756Profs*74) (40.6%)
1105-270*
1105-273* BRCA1:c.4621G>T, p.(Glu1541*)
(31.7%)
1105-024* BRCA2:c.7615C>T, p.(Gln2539*)
(11.1%)
1105-204*
1105-110* BRCA1:c.1116G>A, p.(Trp372*)
(80.1%)
1105-113*

BRCA1del

BRCA1:c.2891delG,
p.(Gly964Aspfs*36) (58.4%)

BRCA1:c.2423_2481del,
p.(Phe808Trpfs*3) (27.1%)
BRCA1del

BRCA1:c.182G>C,
p.(Cys61Ser) (89.2%)

1105-119* BRCA1:c.3967C>T, p.(Gln1323*)
(93.3%)

BRCA2:c.9665G>T, p.(Cys3222Phe) (24%)

1105-123* BRCA1:c.5266dupC,
p.(Gln1756Profs*74) (69.3%)
1105-130*
1105-159*

BRCA1del
BRCA1:c.5096G>A,
p.(Arg1699Gln) (44.6%)

BRCA2dup

1105-185*

BRCA1
exon13dup
BRCA2dup

1105-192* BRCA1:c.68_69delAG,
p.(Glu23Valfs*17) (76.3%)
1105-193*

BRCA1:c.3394_3406del,
p.(Asn1132Leufs*19) (70%)

1105-222*

BRCA1:c.709G>T,
p.(Glu237*) (51.2%)
BRCA1:c.5074G>A,
p.(Asp1692Asn) (72.8%)

1105-246*

BRCA1dup

1105-049* BRCA2:c.7958T>C,
p.(Leu2653Pro) (99.4%)
1105-088* BRCA2:c.3170_3174del,
p.(Lys1057Thrfs*8) (71.4%)
1105-103* BRCA2:c.6591_6592delTG,
p.(Glu2198Asnfs*4) (53.7%)
1105-104* BRCA2:c.7954delG,
p.(Val2652Cysfs*5) (38.5%)

BRCA2:c.9305C>T, p.(Ala3102Val) (43.1%)

1105-111* BRCA2:c.8167G>C,
p.(Asp2723His) (69.6%)
1105-128*

BRCA1:c.-62G>A (57.1%)
BRCA2del

1105-152# BRCA2:c.3545_3546delTT,
p.(Phe1182*) (34%)
1105-200* BRCA2:c.7617+2T>G (63.7%)
1105-202* BRCA2:c.2588dupA,
p.(Asn863Lysfs*18) (67.2%)
1105BRCA2:c.633dupC,
265#*
p.(Arg212Glnfs*3) (45.2%)
1105-139*

BRCA1:c.-86C>T (83.3%)

BRCA2:c.3587T>A,
p.(Leu1196*) (73.3%)
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Table 1 (continued)
Sample ID Tier 1

Tier 2

1105-078*

BRCA2:c.8164dupA,
p.(Thr2722Asnfs*8) (37.3%)

1105-137* BRCA2:c.7069_7070delCT,
p.(Leu2357Valfs*2) (18.7%)
1105-144*

Tier 3 (VUS)

CNVs

BRCA2:c.1094C>T, p.(Pro365Leu) (17.6%)
BRCA2del

1105-258* BRCA2:c.1054dupT,
p.(Tyr352Leufs*6) (72.2%)
1105-268*
1105-041 BRCA1:c.4258C>T, p.(Gln1420*)
(11.9%)
1105-182

BRCA2del

BRCA1:c.5497G>A,
p.(Val1833Met) (10.3%)

BRCA2:c.10112C>T, p.(Thr3371Ile) (10.5%)

1105-036

BRCA1dup

1105-018
1105-022

BRCA2:c.9338T>C, p.(Ile3113Thr) (75.6%)

BRCA1dup

1105-055
1105-059

BRCA1:c.4531C>T, p.(His1511Tyr) (12.2%)

BRCA2dup

1105-120

BRCA2:c.44_45insATT, p.(Ile14_Phe15insLeu) (45.7%) BRCA2:
c.9502–12T>G (82.5%) BRCA2:c.41_67+9del, p.(?) (12.4%)

1105-126
1105-157

BRCA2:c.2716A>G, p.(Thr906Ala) (66.1%)

1105-174
1105-178

BRCA1:c.2212G>A, p.(Val738Ile) (10.2%)
BRCA1:c.5416C>T, p.(Pro1806Ser) (14.7%)

BRCA2dup

1105-181
1105-183
1105-197

BRCA2dup
BRCA1:c.2713C>G, p.(Gln905Glu) (23.9%)

1105-198
1105-220

BRCA2:c.5714A>T, p.(His1905Leu) (43.1%)

1105-229
1105-277

BRCA2:c.9698G>C, p.(Cys3233Ser) (47.7%)

BRCA2dup
BRCA1dup
BRCA2dup
BRCA2dup

Percentages in brackets indicate alternate allele fractions. Due to the presence of varying levels of normal tissue in these tumor specimens, as well
as confounding factors such as chromosomal aneuploidy or copy-number alterations, the true allele fractions in the tumor may be above what is
indicated. Samples with allele fractions above 40% were considered for PARPi therapy. Most of the samples had a tumor percentage >50%. It is
notable that this number may not indicate a heterozygous state in the heterogenous tumors. The samples with residual or low tumor volume
(10–20%) are indicated with a hash sign. The copy-number changes were conﬁrmed with MLPA. Gene duplications are not assessed clinically,
since they are not conﬁrmed to result in recombination deﬁciency. Samples with a Tier 1 or Tier 2 variants or those with truncating intragenic
duplications/full gene deletions are eligible for PARPi therapy. Samples used in methylation testing are indicated with an asterisk

identiﬁed with a pathogenic SNV/indel in BRCA1/2 while
another ~10% will have a pathogenic CNV or a promoter
DNA methylation defect in these genes. DNA methylation
testing, despite the documented effect on PARPis response
rates [23], is not being conducted in the routine assessment
of drug eligibility. Thus, a multi-faceted approach can have
a greater potential in detecting patients that may beneﬁt
from PARPi therapy.
Currently, there is no established guideline regarding the
use of PARPis in ovarian tumors with BRCA promoter
hypermethylation. However, new evidence suggests efﬁcacy of this class of drugs on tumors with such aberrations.
Swisher et al. have reported up to 50% response rate for
Rucaparib, a PARP inhibitor, in ovarian samples that had
BRCA1 promoter hypermethylation [23]. In their cohort of
165 ovarian samples, 12% had hypermethylation in the
BRCA1 promoter, a ﬁgure comparable to those with
sequence variant defects. Another study has found that none

of the ovarian tumors with BRCA1 promoter hypermethylation demonstrate BRCA1 protein expression by immunohistochemistry, being consistent with the silencing of the
BRCA1 gene [8]. This indicates a possible new target
patient population that could beneﬁt from PARPis. The
effectiveness of PARPis in samples with BRCA1/2 promoter
hypermethylation has also been documented in other
tumors, including a clinical trial currently undergoing for
triple-negative breast tumors with BRCA1/2 hypermethylation [24].
Another way DNA methylation testing can beneﬁt the
identiﬁcation of patients eligible for PARPi’s is through the
use of a DNA methylation proﬁle associated with the
BRCAness phenotype. Ovarian tumors with BRCAs mutations are known to have a distinct clinical behavior, mainly
attributed to homologous recombination deﬁciency, leading
to massive genomic instability and affecting many layers of
the regulation of gene expression such as DNA methylation
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Fig. 1 DNA methylation
analysis of BRCA1 promoter.
The ﬁgure illustrates >500 bps
annotating to the promoter of the
BRCA1 gene in individuals with
no sequence variant ﬁndings in
BRCA1/2. The methylation
levels for each CpG site in this
region (0–1) is shown using a
circle, connected to the adjacent
CpGs of the same individual
using a line. The majority of
samples show a
hypomethylation pattern (blue),
while two samples show a gain
of methylation (red)
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Table 2 Accuracy measures for classiﬁcation of ovarian tumors by
BRCA status using DNA methylation data
Accuracy
indicator

Fold 1 Fold 2 Fold 3 Fold 4 Fold 5 Average

Overall
accuracy

0.69

0.81

0.81

0.71

0.73

0.75

Sensitivity

0.67

0.89

0.89

0.8

0.89

0.83

Speciﬁcity

0.71

0.71

0.71

0.57

0.5

0.64

PPV

0.75

0.8

0.8

0.73

0.73

0.76

NPV

0.62

0.83

0.83

0.67

0.75

0.74

AUC

0.68

0.79

0.79

0.8

0.78

0.77

[25]. A DNA methylation pattern speciﬁc to BRCAness can
be used to resolve uncertain cases where, for instance, a
VUS is found in BRCA1/2. Our analysis shows that the
status of BRCA1/2 mutations can be, to some extent, modeled using genomic DNA methylation data. The heterogeneous nature of ovarian tumors, however, may not enable
a full accuracy in the classiﬁcation of the samples into
BRCA1/2 positive/negative proﬁle. A previous study using
DNA methylation data has also reached a comparable
accuracy (~80%) in detecting breast tumors with BRCA1
mutations [26]. A BRCAness phenotype can be present in
tumors with homologous recombination deﬁciency, but
without a defect in BRCA’s expression [27]. It is possible
that some of the non-mutated BRCA tumors in these studies
have had a BRCAness proﬁle, limiting the accuracy of DNA
methylation classiﬁcation. Consistently, the utility of PARPis is shown to be not limited to BRCA1 and BRCA2

41277400

41277600

41277800

41278000

deﬁcient tumors. Any defective homologous recombination
caused by the deﬁciency of other genes can be a potential
target for PARPis therapy. Proteins involved in homologous
recombination repair other than BRCA1 and BRCA2,
including ATM, CHEK2, BARD1, BRIP1, MRE11,
RAD50, NBS1, RAD51C, RAD51D, and PALB2, have
been reported to be associated with increased susceptibility
to ovarian cancer. Several of these have now been associated
with moderate increased susceptibility to ovarian and/or
breast cancer [22, 23, 27–32]. Swisher et al. have reported a
75% response rate by PARPis for RAD51 deﬁcient ovarian
tumors [23]. On a non-gynecological cancer example, there
is emerging evidence that the use of PARPis can potentiate
the action of alkylating agents in glioblastoma tumors that
have hypermethylation of the promoter of MGMT, coding
for another DNA repair protein [33].
These ﬁndings all raise the question of whether a DNA
methylation signature of homologous recombination deﬁciency could be used to better identify patients in need of
PARPi therapy than sequence variant assessment of BRCA1
and BRCA2. Further analyses on larger sample sizes
attempting to map a DNA repair-associated DNA methylation signature that includes all of the involved genes
beyond BRCAs, such as ATM, CHEK2, BARD1, BRIP1,
MRE11, RAD50, NBS1, RAD51C, RAD51D, and PALB2,
followed by clinical trials to evaluate the effectiveness of
PARPis in the group of patients showing such a methylation
proﬁle are needed before the implementation of DNA
methylation proﬁling in clinical testing of ovarian cancer
patients.
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A ﬁnal point to consider about the PARPi eligibility is
about the somatic vs. germline and zygocity status of
the genetic testing ﬁndings. While it is expected that a
proportion of PARP-sensitive tumors exhibit biallelic loss
of BRCA1/2 that may be detectible by this analysis, in the
majority of cases, the identiﬁed mutation, deletion, or
methylation defects appear to occur in a single allele. Based
on the recommendations by the Pan-Canadian Oncology
Drug Review expert review committee, Olaparib monotherapy maintenance treatment is recommended for
BRCA1/2-mutated patients with an evidence of a germline
or somatic defect as detected by approved testing laboratories [34]. Therefore, while this assay is not designed to
determine the germline vs. somatic status or biallelic loss of
BRCA, it meets the requirements for the identiﬁcation of
PARP-eligible individuals.
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